Loading...
Docoh

Aprea Therapeutics (APRE)

Employees
Data from SEC filings
Employee count
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

At the 2021 annual meeting of stockholders (the “Annual Meeting”) of Aprea Therapeutics, Inc. (the “Company”) held on June 9, 2021, the following proposals were submitted to the stockholders of the Company:

Proposal 1:The election of two directors to serve as Class II directors until the Company’s 2024 annual meeting of stockholders and one director to serve as a Class I director for the remainder of a term expiring at the 2023 annual meeting of stockholders and until their successors are duly elected and qualified.

Proposal 2:The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

For more information about the foregoing proposals, please refer to the Company’s proxy statement filed with the Securities and Exchange Commission on April 28, 2021. The number of votes cast for, against, or withheld, as well as abstentions and broker non-votes, if applicable, in respect to each proposal is set forth below:

Proposal 1:Election of Directors

The Company’s stockholders elected the following two directors to serve as Class II directors until the Company’s 2024 annual meeting of stockholders and the following director to serve as a Class I director for the remainder of a term expiring at the 2023 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of the directors were as follows:

Broker Non-
DirectorVotes ForVotes WithheldVotes
Class II Nominees
Johan Christenson, M.D., Ph.D.9,203,832415,4684,149,014
Fouad Namouni, M.D.8,621,227998,0734,149,014
Class I Nominee
Richard Peters, M.D., Ph.D.9,207,831411,4694,149,014

Proposal 2:Ratification of Appointment of Ernst & Young LLP

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The voting regarding this proposal were as follows:

Votes ForVotes AgainstVotes Abstaining
13,696,46352,54019,311